DJIA 15,354.40 121.18 0.80%
NASDAQ 3,498.97 33.73 0.97%
S&P 500 1,667.47 17.00 1.03%

Vertex Pharmaceuticals

NASDAQ: VRTX

+ Add to Portfolio

company name or ticker
Company Photos
(Click to zoom)
Working at Vertex Pharmaceuticals

Pipeline Progresses at ViroPharma - Analyst Blog

4/23/2013 by Zacks

ALS-2200 (VX-135) Viral Kinetic Study Shows Significant Reduction in HCV RNA in People with Genotype

ALS-2200 (VX-135) Viral Kinetic Study Shows Significant Reduction in HCV RNA in People with Genotype 1 Hepatitis C Virus Infection and Cirrhosis, and in People with Genotypes 2, 3 or 4 HCV Infection
4/23/2013 by Benzinga

Catalyst Deserves The Attention

4/23/2013 by Seeking Alpha

Merck In-Licenses from Xenon - Analyst Blog

Merck In-Licenses from Xenon - Analyst Blog
4/22/2013 by Zacks

FDA Approves Novartis' Simbrinza - Analyst Blog

4/22/2013 by Zacks

Market Close Report: NASDAQ Composite index closes at 3,233.55 up 27.49 points

4/22/2013 by Nasdaq

4 Stocks Pushing The Drugs Industry Downward

4/22/2013 by TheStreet

Vertex Stock Falls On Unusually High Volume (VRTX)

4/22/2013 by TheStreet

Today's Market News To Trade On: 5 Stocks Moving On News

4/22/2013 by Seeking Alpha

Market Close Report: NASDAQ Composite index closes at 3,206.06 up 39.70 points

4/19/2013 by Nasdaq
See More Articles...